Longeveron Inc.

Listed Company

LGVNCIK 0001721484NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.20M

Net Income

$-22.70M

Total Assets

$10.26M

Equity

$5.67M

Shares Out

—

Op. Cash Flow

$-18.64M

Business

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines based on allogeneic mesenchymal stem cell therapies. Its primary product is Lomecel-B™, a bone-marrow-derived MSC formulation, and the company also operates cGMP manufacturing and occasional contract development and manufacturing services. Business activities are organized around clinical development programs for hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty, supported by intellectual property, licensing arrangements and manufacturing operations. The company conducts U.S.-based clinical trials, collaborates with government and academic partners, and pursues limited international registry trials and global patent protection.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	1	2	709,000	—	—
Cost of revenues	396,000	508,000	488,000	725,000	716,000
Gross profit	803,000	2	221,000	497,000	590,000
General and administrative	12	10	12	8	10
Research and development	12	8	9	9	7
Total operating expenses	24	18	21	19	18
Loss from operations	−23	−17	−21	−18	−17
Loss on disposal of assets	−97,000	—	—	—	—
Other income (expense), net	680,000	549,000	−377,000	300,000	411,000
Total other income (expenses), net	583,000	549,000	−384,000	−792,000	—
Net loss	−23	−16	−21	−19	—
Deemed dividend - warrant inducement offers	0	−9	−798,000	—	—
Net loss attributable to common stockholders	−23	−25	−22	−19	—
Basic net loss per share	−1.29	−2.62	−10.22	−0.9	−0.9
Diluted net loss per share	−1.29	−2.62	−10.22	−0.9	−0.9
Basic weighted average common shares outstanding	17,577	9,411	2,173	21	19
Diluted weighted average common shares outstanding	17,577	9,411	2,173	21	19

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	5	19	5	11	26
Prepaid expenses and other current assets	686,000	308,000	376,000	404,000	282,000
Accounts and grants receivable	104,000	84,000	111,000	218,000	55,000
Total current assets	5	20	6	20	35
Property and equipment, net	2	2	3	3	3
Intangible assets, net	2	2	2	2	2
Operating lease asset	513,000	882,000	1	2	2
Other assets	176,000	202,000	193,000	244,000	—
Total assets	10	26	12	27	43
Accounts payable	423,000	99,000	638,000	2	645,000
Accrued expenses	3	2	2	650,000	1
Current portion of operating lease liability	655,000	623,000	593,000	564,000	537,000
Deferred revenue	40,000	40,000	506,000	—	—
Total current liabilities	4	3	4	5	3
Long-term portion of operating lease liability	169,000	824,000	1	2	—
Other liabilities	330,000	265,000	0	—	—
Total long-term liabilities	499,000	1	1	2	—
Total liabilities	5	4	5	7	5
Commitments and contingencies (Note 9)	—	—	—	—	—
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024	—	—	—	—	—
Additional paid-in capital	138	131	92	84	81
Accumulated deficit	−132	−110	−85	−63	−44
Total stockholders equity	6	22	7	21	37
Total liabilities and stockholders equity	10	26	12	27	43

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	1	958,000	946,000	893,000	—
Interest earned on marketable securities	0	60,000	220,000	170,000	—
Equity-based compensation	2	2	2	2	1
Loss on disposal of assets	97,000	0	—	—	—
Accounts and grants receivable	−20,000	27,000	107,000	−164,000	366,000
Prepaid expenses and other current assets	−378,000	68,000	28,000	−122,000	−227,000
Other assets	25,000	−9,000	51,000	−15,000	−4,000
Accounts payable	325,000	−540,000	−1	1	−945,000
Deferred revenue	0	−466,000	—	307,000	—
Accrued expenses	1	−332,000	2	−677,000	−214,000
Operating lease asset and liability	−254,000	−254,000	−254,000	—	—
Other liabilities	66,000	265,000	—	—	—
Net cash used in operating activities	−19	−14	−19	−14	−10
Proceeds from the sale of marketable securities	0	352,000	9	179,000	—
Acquisition of property and equipment	−245,000	−655,000	−301,000	−569,000	−330,000
Acquisition of intangible assets	−350,000	−337,000	−393,000	−287,000	−980,000
Net cash used in investing activities	−595,000	−640,000	8	−677,000	−11
Proceeds from the issuance of common stock, net of issuance cost	5	13	5	2,000	27
Proceeds from warrants exercised, net of issuance cost	0	16	98,000	—	—
Proceeds from stock subscription receivable	0	100,000	—	—	—
Payments for taxes on RSUs vested and PSUs vested	−311,000	−366,000	−174,000	—	—
Net cash provided by financing activities	5	29	5	−509,000	45
Change in cash and cash equivalents	−15	14	−6	−15	25
Vesting of RSUs into Class A Common Stock	−797,000	−1	−777,000	—	—
Offering costs in accounts payable and accrued expenses	28,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro